GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4X Discovery Holdings PLC (FRA:C4J) » Definitions » EV-to-EBIT

C4X Discovery Holdings (FRA:C4J) EV-to-EBIT : 1.27 (As of Sep. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4X Discovery Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, C4X Discovery Holdings's Enterprise Value is €14.23 Mil. C4X Discovery Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was €11.18 Mil. Therefore, C4X Discovery Holdings's EV-to-EBIT for today is 1.27.

The historical rank and industry rank for C4X Discovery Holdings's EV-to-EBIT or its related term are showing as below:

FRA:C4J' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.62   Med: -4.28   Max: 1.14
Current: 1.14

During the past 12 years, the highest EV-to-EBIT of C4X Discovery Holdings was 1.14. The lowest was -27.62. And the median was -4.28.

FRA:C4J's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.95 vs FRA:C4J: 1.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. C4X Discovery Holdings's Enterprise Value for the quarter that ended in Jan. 2024 was €19.04 Mil. C4X Discovery Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was €11.18 Mil. C4X Discovery Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was 58.74%.


C4X Discovery Holdings EV-to-EBIT Historical Data

The historical data trend for C4X Discovery Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4X Discovery Holdings EV-to-EBIT Chart

C4X Discovery Holdings Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.80 -1.76 -9.35 -5.42 -3.52

C4X Discovery Holdings Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.42 - -3.52 -

Competitive Comparison of C4X Discovery Holdings's EV-to-EBIT

For the Biotechnology subindustry, C4X Discovery Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4X Discovery Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4X Discovery Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where C4X Discovery Holdings's EV-to-EBIT falls into.



C4X Discovery Holdings EV-to-EBIT Calculation

C4X Discovery Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=14.225/11.184
=1.27

C4X Discovery Holdings's current Enterprise Value is €14.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. C4X Discovery Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was €11.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C4X Discovery Holdings  (FRA:C4J) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

C4X Discovery Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 ) =EBIT / Enterprise Value (Q: Jan. 2024 )
=11.184/19.040645
=58.74 %

C4X Discovery Holdings's Enterprise Value for the quarter that ended in Jan. 2024 was €19.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. C4X Discovery Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was €11.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C4X Discovery Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of C4X Discovery Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


C4X Discovery Holdings Business Description

Traded in Other Exchanges
N/A
Address
53 Portland Street, Manchester One, Manchester, GBR, M1 3LD
C4X Discovery Holdings PLC is a drug discovery and development company. It has various proprietary and synergistic software platforms Taxonomy3, Conformetrix, and 4Sight. Taxonomy3 is a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The 4Sight allows its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules.

C4X Discovery Holdings Headlines

No Headlines